Neutral red uptake (NRU) entseguaren optimizazioa lur-zizareen sistema immuneko zelulen kultibo primarioetan

Azken urteotan eman diren kutsatzaile desberdinen gehiegizko isurpen edo erabilpena dela eta, lurzoruetan metal astunak metatu dira eta horrek , kate trofikoaren oinarrian dauden organismoen gainean k altea k sorrarazi d itu. Eisenia fetida zizarea espezie zent inela gisa erabili da lur entsegu ekotoxikologi koet an . Esperimentu honetan Eisenia fetida - ren jariakin zelomikoan dauden eta babes funtzioa duten zelomozitoak pH desberdinetara edo Kadmio bezalako metalera esposatzeak Neutral Red (NR) edo gorri neutro tindatzaile kationikoaren harreran eta fagoz itosi ahalmenean , eragina duen aztertu nahi izan da. Esperimentua in vitro egin zen 3R filosofia jarraituz. Alde batetik, pH desberdinen eragin ari dagokio nez gorri neutroaren harrera ( NRU ) entsegua n erantzun bimodal bat behatu zen eta beste alde bate tik, f agozitatzeko ahalmenari dagokiola zelomozitoak Eagle medioan kultibatzean ez zen aldaketa esangarria ikusi kadmioa ren, kontr olaren eta kontrol positi boaren artean. Bai ordea L - 1 5 medioarekin, non kontrol posit iboa k beste biak baino absorbantzia handiagoa erakutsi zuen. Emaitza hauek erakusten dute zelomozitoe n mintza gradualki kaltetzen doala pH neutrotik aldentzen doan heinean eta puntu batetik aurrera NRU emendatzen da zelomozito batzuen (amebozitoen) fagozitosia aktibatzen d el a ko .

Lymphangioleiomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell Stemness

Lymphangioleiomyomatosis (LAM) is a rare lung-metastasizing neoplasm caused by the proliferation of smooth muscle-like cells that commonly carry loss-of-function mutations in either the tuberous sclerosis complex 1 or 2 (TSC1 or TSC2) genes. While allosteric inhibition of the mechanistic target of rapamycin (mTOR) has shown substantial clinical benefit, complementary therapies are required to improve response and/or to treat specific patients. However, there is a lack of LAM biomarkers that could potentially be used to monitor the disease and to develop other targeted therapies. We hypothesized that the mediators of cancer metastasis to lung, particularly in breast cancer, also play a relevant role in LAM. Analyses across independent breast cancer datasets revealed associations between low TSC1/2 expression, altered mTOR complex 1 (mTORC1) pathway signaling, and metastasis to lung. Subsequently, immunohistochemical analyses of 23 LAM lesions revealed positivity in all cases for the lung metastasis mediators fascin 1 (FSCN1) and inhibitor of DNA binding 1 (ID1). Moreover, assessment of breast cancer stem or luminal progenitor cell biomarkers showed positivity in most LAM tissue for the aldehyde dehydrogenase 1 (ALDH1), integrin-beta 3 (ITGB3/CD61), and/or the sex-determining region Y-box 9 (SOX9) proteins. The immunohistochemical analyses also provided evidence of heterogeneity between and within LAM cases. The analysis of Tsc2-deficient cells revealed relative over-expression of FSCN1 and ID1; however, Tsc2-deficient cells did not show higher sensitivity to ID1-based cancer inhibitors. Collectively, the results of this study reveal novel LAM biomarkers linked to breast cancer metastasis to lung and to cell stemness, which in turn might guide the assessment of additional or complementary therapeutic opportunities for LAM.